PF-05231023

Research use only, not for human use.

PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM. PF-05231023 is a analog of long-acting fibroblast growth factor 21.

PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM. PF-05231023 is a analog of long-acting fibroblast growth factor 21.PF-05231023 suppresses oxidative-stress-induced inflammation in photoreceptors. PF-05231023 decreases the variability of retinal NRF2 levels and displays a trend (non-significant) towards increased NRF2 levels in Akita mice. PF-05231023 decreases retinal IL-1β mRNA expression in Akita mice. PF-05231023 enhances cone-specific arrestin4 expression in Akita mice. PF-05231023 restores photoreceptor morphology in Akita mice. Administration of native FGF21 and PF-05231023 (3?mg/kg or 10?mg/kg; subcutaneously twice a week for two weeks) improves glucose tolerance and liver insulin sensitivity in Zucker rats. PF-05231023 (10 mg/kg; intraperitoneally injected) reduces retinal inflammation in diabetic mice.(In Vivo):Animal Model: Eight week old Zucker ratsDosage: 3?mg/kg and 10?mg/kg.Administration: Subcutaneously twice a week for two weeks.Result: There was no change of BW observed, and food intake was not changed in the treated groups compared to control. Caused a significant decrease of glucose excursion during the oral glucose tolerance test (OGTT) compared to control.

——

Animal Model:Eight week old Zucker rats Dosage:3?mg/kg and 10?mg/kg Administration:Subcutaneously twice a week for two weeksResult:There was no change of BW observed, and food intake was not changed in the treated groups compared to control. Caused a significant decrease of glucose excursion during the oral glucose tolerance test (OGTT) compared to control. Animal Model:7-to-8-month-old Akita mice with type 1 diabete model Dosage:10 mg/kg Administration:Intraperitoneally injected; twice a week; for four weeks Result:Administration improved retinal function in diabetic Akita mice.

——

Others

Other Targets

FGF21-receptor

——

——

1037589-69-7

528.55

C26H32N4O8

>98% (HPLC)

DMSO:125 mg/mL (236.50 mM; Need ultrasonic)

O=C(CCN1C(=O)C=CC1=O)NCCOCCOCCC(=O)Nc1ccc(CCC(=O)N2CCC2=O)cc1

——

(-20℃)

With Ice Pack

≥ 2 years